MedPath

DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. logo
🇯🇵Japan
Ownership
Subsidiary
Established
2010-01-01
Employees
10K
Market Cap
$79B
Website
http://daiichisankyo.us

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Phase 1
Completed
Conditions
Netherton Syndrome
Interventions
Drug: Placebo
First Posted Date
2022-05-24
Last Posted Date
2023-03-06
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
64
Registration Number
NCT05388903
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 3
Active, not recruiting
Conditions
Nonsquamous Non-small Cell Lung Cancer
EGFR L858R
EGFR Exon 19 Deletion
Interventions
Drug: Platinum-based chemotherapy
First Posted Date
2022-04-21
Last Posted Date
2025-01-31
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
586
Registration Number
NCT05338970
Locations
🇺🇸

Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

🇺🇸

Highlands Oncology, Springdale, Arkansas, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 176 locations

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Phase 2
Active, not recruiting
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Drug: Ifinatamab Deruxtecan (I-DXd)
First Posted Date
2022-03-15
Last Posted Date
2025-05-14
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
187
Registration Number
NCT05280470
Locations
🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

🇺🇸

The Cancer Specialists, Llc, Jacksonville, Florida, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 55 locations

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Phase 3
Recruiting
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
First Posted Date
2022-01-31
Last Posted Date
2025-06-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
740
Registration Number
NCT05215340
Locations
🇺🇸

Ironwood Cancer and Research Center, Chandler, Arizona, United States

🇺🇸

UCLA HemOnc - Clinical Research Unit, Los Angeles, California, United States

🇺🇸

Compassionate Cancer Care Medical Group, Riverside, California, United States

and more 237 locations

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

Phase 1
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: Placebo
First Posted Date
2022-01-24
Last Posted Date
2023-04-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
80
Registration Number
NCT05203692
Locations
🇺🇸

Apex Clinical Research (Collaborative Neuroscience Research), Long Beach, California, United States

🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia

Active, not recruiting
Conditions
Dyslipidemia
Interventions
First Posted Date
2021-11-15
Last Posted Date
2024-07-05
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
3300
Registration Number
NCT05120895
Locations
🇰🇷

Soon Chun Hyang University Hospital Bucheon, Bucheon-si, Korea, Republic of

🇰🇷

Bucheon Sejong Hospital, Bucheon, Korea, Republic of

🇰🇷

Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 55 locations

An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

Completed
Conditions
Dyslipidemia Associated With Type II Diabetes Mellitus
Interventions
First Posted Date
2021-11-04
Last Posted Date
2021-11-04
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
2972
Registration Number
NCT05107063
Locations
🇰🇷

Korea University Ansan Hospital, Ansan, Korea, Republic of

🇰🇷

The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of

🇰🇷

Yeongnam University Medical Center, Busan, Korea, Republic of

and more 44 locations

Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings

Completed
Conditions
Pseudoxanthoma Elasticum
Interventions
Other: Non Interventional
First Posted Date
2021-08-27
Last Posted Date
2022-09-06
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
48
Registration Number
NCT05025722
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: 14C-Quizartinib solution for infusion
First Posted Date
2021-03-15
Last Posted Date
2023-01-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
8
Registration Number
NCT04796831
Locations
🇬🇧

Quotient Sciences, Nottingham, United Kingdom

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

Completed
Conditions
Non-valvular Atrial Fibrillation
Interventions
First Posted Date
2021-02-10
Last Posted Date
2025-01-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
5000
Registration Number
NCT04747496
Locations
🇨🇳

Beijing Tsinghua Changgung Hospital Affiliated Hospital of Tsinghua University, Beijing, Changping District, China

🇨🇳

Aviation General Hospital of China Medical University, Beijing, Chaoyang District, China

🇨🇳

Beijing Anzhen Hospital, Capital Medical University, Beijing, Chaoyang District, China

and more 93 locations
© Copyright 2025. All Rights Reserved by MedPath